A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanoma - Ph Ib/II study of AEB071+MEK162 in patients with metastatic uveal melanoma

ovartis0 个研究点目标入组 12 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1. Male or female patients >=18 years of age
•2. Uveal (ocular) melanoma with biopsy-confirmed metastatic disease
•3. Consent to a new tumor biopsy at baseline, Cycle 1 Day 15 (C1D15), and at disease progression
•4. The presence of measurable disease according RECIST v1.1
•5. WHO performance status of <=1

•1. Any active metastatic CNS lesion
•2. History of prior or current second malignancy (except adequately treated carcinoma of the cervix or localized basal cell carcinoma of the skin, or any other curatively treated malignancy that has not been treated or recurred in the past 3 years).
•3. History or current evidence of retinal vein occlusion (RVO) in the contralateral eye, as assessed by ophthamologic examination at baseline or current risk factors for RVO.
•4. Impaired cardiac function ro clinically significant cardiac disease; e.g. , LVEF < 50% as determined by MUGA scan or TTE
•5. Serum creatinine of >1.5x ULN
•6.Treatment with strong inducers or inhibitors (medications and herbal supplements) of cytochrome P450 3A4/5 (CYP3A4/5) or CYP3A4/5 substrates with a QT prolongation risk that cannot be discontinued at least 7 half lives (or if the half-life is unkonw, 14 days) prior to study drug treatment.
•7.Prior exposure to a MEK or PKC inhibitor (i.e. patients treated in the Phase I will not be eligible for the Phase II)

发起方